Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Fenech, Rachel K.a | Hamstra, Sophie I.b | Finch, Michael S.a | Ryan, Chantal R.a | Marko, Daniel M.a | Roy, Brian D.b | Fajardo, Val A.b | MacPherson, Rebecca E.K.a; c; *
Affiliations: [a] Department of Health Sciences, Brock University, St. Catharines, ON, Canada | [b] Department of Kinesiology, Brock University, St. Catharines, ON, Canada | [c] Centre for Neuroscience, Brock University, St Catharines, ON, Canada
Correspondence: [*] Correspondence to: Rebecca E.K. MacPherson, PhD, Brock University, Department of Health Sciences, Faculty of Applied Health Sciences, St. Catharines ON, L2S 3A1, Canada. E-mail: [email protected].
Abstract: Background:Lithium, a commonly used treatment for bipolar disorder, has been shown to have neuroprotective effects for other conditions including Alzheimer’s disease via the inhibition of the enzyme glycogen synthase kinase-3 (GSK3). However, dose-dependent adverse effects of lithium are well-documented, highlighting the need to determine if low doses of lithium can reliably reduce GSK3 activity. Objective:The purpose of this study was to evaluate the effects of a low-dose lithium supplementation on GSK3 activity in the brain of an early, diet-induced Alzheimer’s disease model. Methods:Male C57BL/6J mice were divided into either a 6-week or 12-week study. In the 6-week study, mice were fed a chow diet or a chow diet with lithium-supplemented drinking water (10 mg/kg/day) for 6 weeks. Alternatively, in the 12-week study, mice were fed a chow diet, a high-fat diet (HFD), or a HFD with lithium-supplemented drinking water for 12 weeks. Prefrontal cortex and hippocampal tissues were collected for analysis. Results:Results demonstrated reduced GSK3 activity in the prefrontal cortex as early as 6 weeks of lithium supplementation, in the absence of inhibitory phosphorylation changes. Further, lithium supplementation in an obese model reduced prefrontal cortex GSK3 activity as well as improved insulin sensitivity. Conclusion:Collectively, these data provide evidence for low-dose lithium supplementation to inhibit GSK3 activity in the brain. Moreover, these results indicate that GSK3 activity can be inhibited despite any changes in phosphorylation. These findings contribute to an overall greater understanding of low-dose lithium’s ability to influence GSK3 activity in the brain and its potential as an Alzheimer’s disease prophylactic.
Keywords: Alzheimer’s disease, brain, GSK3, insulin, lithium
DOI: 10.3233/JAD-220813
Journal: Journal of Alzheimer's Disease, vol. 91, no. 2, pp. 615-626, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]